T2 Biosystems' Shares Gain As FDA Grants Breakthrough Device Status To Lyme Disease Diagnosis

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for T2 Biosystems’ (NASDAQ: TTOO ) T2Lyme Panel, intended to test individuals with signs and symptoms of Lyme disease and aid in the diagnosis of early Lyme disease. The regulatory grant follows the decision by the U.S. Patent and Trademark Office to grant T2 Biosystems a patent covering the T2Lyme Panel. John Sperzel, ... Full story available on Benzinga.com